News Release/Quick Overview Nuresene announced that Dr. Joseph Geraci ($MEND’s CSO and co-founder of NetraMark) would present research on ALS at the EndALS Pitch Day hosted by Kaggle, a data science subsidiary of Google. “Dr. Geraci helped judge the winning solutions over the past few days and supported Kaggle to discover a set of new drug targets and repurposing candidates, leveraging NetraMark's AI solutions to identify unique features that distinguished different aspects of ALS. NetraMark has been invited to present novel research at the EndALS Kaggle Pitch Day, alongside the competition winners.”
https://ca.finance.yahoo.com/news/nurosenes-chief-scientific-officer-dr-140000367.html
So what is Nurosene?
- They’re a company focused on mental health and wellness, combining movement, brain, nutrition, and recovery with technology to help improve health for users. (The 4x4 model)
- Their app, Nuro, leverages machine learning and cutting edge research to assist those struggling with mental health or looking to create better habits
- Netramark (a wholly owned subsidiary) is another driver for the business. The AI is used by companies all over the pharma development stages, helping boost efficiency and effectiveness of research and development
$MEND is also Purpose Investments top holding in the small cap fund managed by Bruce Campbell. (4.55% of the Canadian Equity Growth Fund). And with $56 AUM, the 4.55% is worth around $2.55M or just about 4.5% of $MEND.
Credits to Allstreets for this one: https://twitter.com/allstreetswolf/status/1458138629339959298?s=21
Considering future potential and what they’ve already been able to accomplish, the current market cap of $57M is fairly undervalued. I’ll be keeping a close eye on $MEND. Also, just listened to an interesting podcast with Dr. Garaci. He goes over his life story, and $MEND, worth a listen.
https://open.spotify.com/episode/1z1ZgOPIQEYr0mtt60dT82?si=fuXvpdkDRvqkG76AbCCdaQ